What's on this Page
DiphtheriaTetanus Toxoids Pertussis Vaccine Haemophilus influenzae type b Conjugate Vaccine Brand Names- ActHIB With DTP | TriHIBit
What is DiphtheriaTetanus Toxoids Pertussis Vaccine Haemophilus influenzae type b Conjugate Vaccine
Diphtheria toxoids tetanus toxoids pertussis vaccine Haemophilus influenzae type b conjugate vaccine (TriHIBit) is a combination vaccine created when Tripedia (diptheria toxoids; tetanus toxoids; acellular pertussis vaccine adsorbed [DtaP]), which is a liquid formulation, is used to reconstitute ActiHIB (Haemophilus influenzae type b conjugate vaccine [Hib]).
The combination product is indicated for the active immunization of children 15—18 months of age who have completed primary immunization with DTP and Hib vaccines.
Clinical trials have indicated that when TriHIBit is administered to children less than 15 months of age, the immune response to the Hib portion of the vaccine is not as great as that which occurs when ActHIb is administered alone; therefore TriHIBit should not be used in children less than 15 months of age for primary immunization.
TriHIBit was approved by the FDA in 1996.
Indications
- diphtheria prophylaxis
- Haemophilus influenzae type b prophylaxis
- pertussis prophylaxis
- tetanus prophylaxis
Side Effects
- aluminum toxicity
- anaphylactic shock
- anaphylactoid reactions
- angioedema
- anorexia
- apnea
- arthralgia
- bronchospasm
- chills
- cyanosis
- diarrhea
- drowsiness
- dyspnea
- encephalopathy
- erythema
- fever
- Guillain-Barre syndrome
- headache
- hemolytic anemia
- hypoesthesia
- hypotension
- hypotonia
- inconsolable crying
- increased intracranial pressure
- injection site reaction
- irritability
- lethargy
- lymphadenopathy
- maculopapular rash
- muscle paralysis
- myelitis
- nausea
- neuritis
- paresthesias
- peripheral neuropathy
- pruritus
- purpura
- rash
- renal failure (unspecified)
- seizures
- syncope
- thrombotic thrombocytopenic purpura (TTP)
- urticaria
- vomiting
- weakness
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- anticoagulant therapy
- bleeding
- breast-feeding
- children
- coagulopathy
- coma
- encephalopathy
- fever
- Guillain-Barre syndrome
- hemophilia
- human immunodeficiency virus (HIV) infection
- immunosuppression
- infants
- infection
- intraarterial administration
- intravenous administration
- latex hypersensitivity
- leukemia
- lymphoma
- neonates
- neurological disease
- pregnancy
- seizure disorder
- seizures
- severe combined immunodeficiency (SCID)
- shock
- subcutaneous administration
- thimerosal hypersensitivity
- thrombocytopenia
- vitamin K deficiency
Interactions
- Ocrelizumab
- Siponimod